"The problem for CHM is that the NK platform performs well but...

"The problem for CHM is that the NK platform performs well but not well enough to be at the forefront of about 300 trials targeting CD19 and that the front runners GBM performs well and CDH17 could perform well but aren't seen by the market as having a realistically positive commercial outcome at this stage."

I agree that CD19 is super competitive. But then how do you then explain IMU and ALA's valuations?

I disagree with your assertion that the CORE NK results are not very promising. we have multiple complete responses in the case western trial. furthermore, MD Anderson, the leading cancer centre in the world and responsible for something like 7 out of the last 8 FDA approvals in AML chose to sponsor a clinical trial (ADVENT AML) using CORE NK and other combo therapy. Dr Maiti from MD Anderson said if we can improve outcomes by 20% over existing standard of care for these high risk AML patients, we can expect breakthrough therapy designation from the FDA.

Whereas the CLTX CART therapy for glioblastoma is unique. Derived from scorpion venom it selectively targets MMP antigen on glioblastoma. Prelim data from CHM during the Phase 1A in very late stage patients (over 66% of patients had a 4+ demonstrated that the CLTX CART is significantly better than current standard of care. I expect even better results with the Phase 1B trial because it will be targeting second line patients and administration protocol (incl pre CART lymphodepletion) will be improved.

So there is a lot to be excited about! In addition to the lead therapy - CDH17 CART.